MILLENNIUM PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C
- First Posted Date
- 2012-04-16
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT01577758
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT01549951
- Locations
- 🇺🇸
Pinnacle Oncology, Scottsdale, Arizona, United States
A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas
- First Posted Date
- 2012-01-19
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01512758
- Locations
- 🇸🇬
National Cancer Centre, Tiong Bahru, Singapore
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-12-14
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01492088
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 271
- Registration Number
- NCT01482962
Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 112
- Registration Number
- NCT01454076
Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer
- First Posted Date
- 2011-10-10
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT01449370
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 149
- Registration Number
- NCT01425008
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2018-03-27
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT01397825
Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-06-28
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01383928
- Locations
- 🇺🇸
Virginia Cancer Specialists PC, Fairfax, Virginia, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
© Copyright 2024. All Rights Reserved by MedPath